FXCM Pro Announces Liquidity Bridging Partnership With Tools for Brokers
5.9.2023 11:00:00 EEST | Business Wire | Press release
FXCM Pro, the institutional arm of FXCM, a leading international provider of online foreign exchange trading, CFD trading and related services has announced a liquidity bridging partnership with Tools for Brokers (TFB), an international technology provider for retail brokers, prop trading companies, and hedge funds.
FXCM Pro will be streaming its institutional liquidity directly to TFB clients, enabling them to connect pricing and trading to their MT4 and MT5 platforms using TFB’s FIX API server. With this new partnership, FXCM Pro’s clients will benefit from having an additional option when selecting a technology/bridge provider.
TFB’s Trade Processor bridge works with the MT4 and MT5, cTrader, Match-Trader, and other platforms and supports third-party integrations via external FIX API. Additionally, it provides brokers with data analysis and enhanced risk management, all through a simple, user-friendly interface.
Mario Sanchez, Managing Director and Global Head of FXCM Pro Sales, commented: “At FXCM Pro, we are committed to providing our clients with the technology they need to succeed, and this is demonstrated in our partnership with Tools for Brokers. This collaboration gives our clients additional choice when it comes to selecting a bridging provider and by selecting TFB, they will benefit from fast execution, automation and improved market access.”
Alexey Kutsenko, CEO at Tools for Brokers, said, “We are excited to partner with FXCM Pro. Under the partnership, FXCM Pro’s clients will benefit from advanced and fast execution without compromising quality or security. Combining our experience and expertise will create a strong platform for many brokerages and hedge funds, allowing them to scale faster and more sustainably.”
FXCM Pro provides retail brokers, small hedge funds and emerging market banks access to wholesale execution and liquidity, while providing high and medium frequency funds access to prime brokerage services via FXCM Prime. Its relationships with tier 1 banks and non-bank liquidity providers, prime broker relationships and technology vendors provide clients with best-in-class market access.
Tools for Brokers (TFB) is an international technology provider for retail brokers, prop trading companies, and hedge funds operating on multiple platforms, including MetaTrader, Match-Trader, and cTrader. It offers an ecosystem of solutions centred around the flagship Trade Processor liquidity bridge, supported by data management and reporting, money management, and a single web-user interface for individual solutions’ management.
For more information on FXCM, please visit http://www.fxcm.com/
For more information on TFB, please visit https://t4b.com/
###
Disclaimers:
This communication is intended for institutional and professional clients only.
About FXCM:
FXCM is a leading provider of online foreign exchange (FX) trading, CFD trading, and related services. Founded in 1999, the company's mission is to provide global traders with access to the world's largest and most liquid market by offering innovative trading tools, hiring excellent trading educators, meeting strict financial standards, and striving for the best online trading experience in the market. Clients have the advantage of mobile trading, one-click order execution and trading from real-time charts. In addition, FXCM offers educational courses on FX trading and provides trading tools, proprietary data and premium resources. FXCM Pro provides retail brokers, small hedge funds and emerging market banks access to wholesale execution and liquidity, while providing high and medium frequency funds access to prime brokerage services via FXCM Prime.
About Tools for Brokers:
Tools for Brokers (TFB) is a multiplatform technology provider for retail brokers, prop trading companies, and hedge funds with solutions operating on MetaTrader, Match-Trader, and cTrader. The ecosystem of products centers around the Trade Processor liquidity bridge, enhanced with data management and reporting functionality, TFB PAMM for money management, and the TFB Toolbox — a single web-user interface for individual custom solutions’ management. The flagship multiplatform liquidity bridge solution — Trade Processor — supports a pool of liquidity providers, helps clients manage risks, collects data, and automates the most critical processes all through a single console.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905624094/en/
Contact information
FXCM Media contact:
Chatsworth Communications
+44 (0) 20 7440 9780
fxcm@chatsworthcommunications.com
Tools for Brokers contact:
Yulia Ogorodnikova
y.ogorodnikova@t4b.com
Tel: +447503599088
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Techtronic Industries Delivers Strong First Half Performance4.8.2026 14:20:00 EEST | Press release
Techtronic Industries Co. Ltd. (“TTI” or the “Group”) (stock code: HK: 0669, ADR symbol: TTNDY), a global cordless power tool, outdoor power equipment and floorcare & cleaning company, is pleased to announce its results for the six-month period ended June 30, 2026. The Group delivered record first half results in 2026, with revenue growing 5.9% to US$8.3 billion. Its two leading brands, MILWAUKEE and RYOBI, both delivered a strong performance in the first half of 2026, growing at a combined 8.2% underlying growth rate in local currency. TTI delivered record first half results in 2026, with revenue growing 5.9% to US$8.3 billion and net profit increasing 17.5% to US$738 million. Our global MILWAUKEE business grew 10.5% on an underlying basis in local currency, after adjusting for the planned 2025 timing impact related to the MILWAUKEE Americas ERP system conversion. RYOBI, the #1 global consumer cordless tool and outdoor products brand, grew 1.7% in local currency to US$1.9 billion in t
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 12:00:00 EEST | Press release
WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, uses biomarker data, including temperature and heart rate data, to identify fertile and non-fertile days, helping users prevent pregnancy without hormones while also providing fertility insights. Beyond birth control, the app
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 11:00:00 EEST | Press release
Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphatax's long-term vision for the future of tax technology. By bringing these transfer pric
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom